Trial Profile
Effect of rasagiline on [18F]THK5351 uptake in patients with progressive supranuclear palsy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Fluorine 18 THK 5351 (Primary) ; Rasagiline (Primary)
- Indications Progressive supranuclear palsy
- Focus Diagnostic use
- 30 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017